Skip to main content
BioCentury on BioBusiness
Feature Story

Vax populi

How Pfizer is expanding its vaccine pipeline

By Jennifer Rhodes, Staff Writer

With a new focus on maternal vaccines, Pfizer Inc. continues to expand its vaccine portfolio beyond preventing disease in children and adolescents, to include therapeutic and prophylactic products that span indications from RSV and meningitis to asthma, dyslipidemia and cancer.

"We're equally excited not just in preventing disease but also the broader aspect of treating disease," said President of Worldwide R&D Mikael Dolsten at a July 21 briefing on Pfizer's vaccines strategy and R&D priorities. "We think it's just the start of a new era where we will encounter vaccines early in life through the vaccination of the mother, then traditional vaccinations in children and adolescents, through to older adults where the attenuation of the immune system makes them susceptible to disease."

Read Article

Today's Biotech & Pharma News

  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial

Management Updates

There were no items published for this section in the most recent issue. Click more >> to read previously published items.

Preclinical Results

There were no items published for this section in the most recent issue. Click more >> to read previously published items.